Moneycontrol.com | Cancer trials show one year on Roche's Herceptin is best Reuters LONDON (Reuters) - Extending treatment with Roche's breast cancer drug Herceptin to two years from the one year current standard is not worth while, trial data showed on Monday, but shortening treatment to six months also looks unlikely to benefit ... C ancer trials show 1 year on Roche's Herceptin is best New findings on optimal duration of trastuzumab therapy for women with HER2+ ... |
Monday, October 1, 2012
Cancer trials show one year on Roche's Herceptin is best - Reuters
iqukikofor.wordpress.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment